Agimexpharm Pharmaceutical JSC

Agimexpharm's capital structure is heavily leveraged, with a debt-to-equity ratio of 1.36, indicating a significant reliance on long-term debt to finance operations. The company's liquidity position is weak, as evidenced by a negative free cash flow of -34,007,277,250 VND and zero cash and equivalents, which raises concerns about its ability to meet short-term obligations. The current ratio of 1.14 suggests that the company has just enough current assets to cover its current liabilities, but not with a significant buffer.

In terms of profitability, Agimexpharm's return on equity (ROE) of 3.2% and return on assets (ROA) of 1.2% are below the industry median for pharmaceutical companies, which typically report ROE and ROA in the 8-12% and 4-6% ranges, respectively. This indicates that the company is underperforming relative to its peers in generating returns for shareholders and utilizing its assets efficiently.

The company's revenue is concentrated in a single geographic market, Vietnam, with no disclosed international operations. This lack of geographic diversification increases exposure to local economic and regulatory risks, such as changes in healthcare policy or currency fluctuations. There are no disclosed segments beyond the core pharmaceutical business, suggesting a lack of diversification in product lines or customer bases.

Looking ahead, Agimexpharm's growth trajectory is uncertain. The company reported a revenue of 189,618,431,720 VND in the latest period, but there is no disclosed revenue growth rate or outlook for the next fiscal year. The negative operating cash flow of -19,981,968,720 VND and a capital expenditure of -76,003,587,400 VND suggest that the company is investing heavily in its operations, which could either signal expansion or financial strain.

The risk assessment highlights several concerns for Agimexpharm. The company's liquidity risk is rated as medium, primarily due to its negative free cash flow and lack of cash reserves. The dilution risk is low, as there is no indication of share buybacks or new equity issuance in the near term. However, the company's high debt load and negative net cash position are red flags for potential financial distress.

Recent events, such as the company's financial performance and capital structure, are reflected in its latest financial statements. There are no disclosed recent filings or transcripts that provide additional insight into the company's strategic direction or operational performance.

Revenue grew at a 12.8% CAGR over four years, demonstrating consistent top-line expansion for the pharmaceutical company.

Net income increased at an 11.9% CAGR over four years, indicating sustained profitability growth alongside revenue expansion.

Net margin of 6.3% outperforms the cohort median of 3.9%, reflecting strong bottom-line performance compared to industry standards.

Free cash flow improved by 95.8% year-over-year, signaling a significant recovery in cash generation capabilities recently.

Debt-to-equity ratio of 1.36 is in the bottom quartile versus the cohort median of 0.18, indicating excessive leverage.

The company faces high credit risk, suggesting potential difficulties in meeting financial obligations or securing favorable financing terms.

Cash conversion ratio of -1.67 is in the bottom quartile versus the cohort median of 0.95, showing poor cash generation.

Return on equity of 3.2% is only marginally above the cohort median of 2.9%, indicating limited value creation for shareholders.